Yuri Deigin Profile picture
Jan 9, 2022 11 tweets 5 min read Read on X
🧵

So I took a look at the 1989 Malone et al. paper cited as proof of his "mRNA vaccines inventorship" to see what the invention was. If I read it correctly, what they did is take the known method of DNA lipofection (delivering DNA into cells using lipids) and applied it to RNA:
Also, as they state in the opening paragraph, other groups have already shown ways to deliver RNA into cells years before:

"By comparison, progress in introducing RNA molecules into cells has been very slow and restricted to a few cases (1-4)."

2nd pic has those references 1-4:
Regarding Malone's 5 patents — all of them were actually filed by Vical *after* Malone left Vical in 1989, and probably carry his name only because they all are continuations of application US32630589A filed in March 1989 (this way the 5 patents all get the 1989 priority date).
Malone is not the first author on any of those 5 patents, and interestingly, the first author of those patents, Philip L. Felgner, has patents on liposomes and vaccines filed long before Malone did his work on RNA lipofection I mentioned above.
This is probably why the 1990 article on Vical's technology mentions Malone only as "other collaborators":

latimes.com/archives/la-xp…
So Malone was briefly involved in the field of liposomal DNA/RNA transfection in late 1980s, along with many others. Has he individually made any groundbreaking contributions to the field to deserve the title of "the inventor of mRNA vaccines"? Doesn't look that way to me.
Oh, and Felgner has actually published on using cationic lipofection of DNA and RNA *before* Malone:
Intriguingly, to support his claims that Felgner "stole" his invention, Malone has published some of his correspondence with Felgner where he seems to acknowledge that the idea to try Felgner's lipofection technique (Malone's words) came from Felgner:

static1.squarespace.com/static/550b0ac…
Malone's time at Vical was quite short: he resigned just a few months after they filed the initial patent application. In his resignation letter Malone stated that he felt that Felgner was taking credit for Malone's contributions:
Now, if Felgner, building on his previous success with DNA lipofection, commissioned Malone to try his lipofection method on RNA and provided Malone with the actual lipid mixtures, how much credit for inventing not even mRNA vaccines but just mRNA lipofection can Malone claim?
PS: I think this thread wouldn’t be complete without this observation about how Malone didn’t even claim to be the inventor of mRNA vaccines until May 2021:

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Yuri Deigin

Yuri Deigin Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ydeigin

Mar 15
Latest SARS2 preprint provides additional evidence that not only was the novel FCS a key factor in its pandemic potential, but the way the FCS was acquired — via a 4 aa insertion — was also important. Re: "why would a genetic engineer use an insertion to create an FCS?"

1/
I've hypothesized previously that the answers to "why use an insertion" and "why use a leading proline" lie in MERS, whose S1/S2 loop is 4 AAs longer than that of SARS-like CoVs, and also has the leading proline, making it more exposed to proteases:

So the desire to try a MERS-like FCS can explain both. Moreover, in the 3D structure of the spike protein, the S1/S2 loop in SARS2 with the insertion has its cleavage point ~3x closer to the MERS one than if the FCS in SARS2 arose w/o insertion:

Read 9 tweets
Mar 14
Increasing neuroinvasiveness could indeed have been the research goal of a genetic engineer opting to use a “suboptimal” or “non-canonical” furin cleavage site like the one found in SARS2. And Baric did say that MHV and FIPV inspired the FCS interest of DEFUSE. Thread below:
Somewhat counterintuitively, in a human coronavirus, OC43, when it has the less efficient (“suboptimal”) RRSR furin cleavage site instead of the canonical RRSRR one, it is more lethal and more *neurovirulent* when tested in a mouse model:

journals.plos.org/plospathogens/…
But in a mouse hepatitis virus (MHV, one inspiration in DEFUSE) it is actually the JHM strain with the more efficient FCS, RRARR (reminiscent of RRAR in SARS2), that is *more* neuroinvasive and more lethal than the A59 strain with a suboptimal RRAHR FCS:

cell.com/trends/pharmac…
Read 10 tweets
Dec 28, 2024
Excellent analysis of SARS2 cryptic lineages from persistent human infections (those nightmare scenarios happen when the virus colonizes your gut and remains there for months or years). Some implications for Covid origins there that I’d like to address in the thread below.
First an aside on extrapolating insertions found in SARS2 circulating in humans to the likelihood of insertions occurring (and getting fixed) in a SARS2 progenitor circulating in an intermediate host — SARS2 has now been circulating for years in hundreds of millions of humans, while in the wild it could not have had even a sliver of such a reservoir of non-bat hosts (and we all agree the FCS insertion could not have arisen in bats because it is detrimental to their preferred enteric tropism).
Of course, “a long time” for passaging in a lab could be just a few months, especially if we’re talking about in vitro passaging. Moreover, many novel mutations would arise quickly when the virus is put into cells from a novel host and organ system (respiratory vs. enteric).
Read 7 tweets
Dec 18, 2024
🧵 Covid Origins: Lab leak critics claim the coincidence of a novel coronavirus emerging near the Wuhan Institute of Virology is dwarfed by the “counter-coincidence” of it first being noticed at a wildlife market. But the market was actually one of the most likely places for a lab-leaked virus to get noticed.

Here’s a clip from my podcast with @robertwrighter and a deep dive in the thread below:
Basically, if we imagine the map of Wuhan as a “probability landscape”, where each location has an inherent probability that a roaming lab-leaked virus would get noticed if it got there, the Huanan seafood market would dominate that landscape like Mount Everest.
Now, let’s walk through the thought experiment: How would a lab-leaked virus get noticed in Wuhan in late 2019?
Read 16 tweets
Nov 29, 2024
Some critics of the Covid lab leak hypothesis say the SARS2 furin cleavage site is unlikely to have been engineered because in previous cases of creating novel FCSes in coronaviruses virologists have never inserted an FCS but rather created them in place via point mutations. But!
A close collaborator of Zhengli Shi and the Wuhan Institute of Virology, Shibo Jiang, in 2013 published a paper creating a furin cleavage site in a non-CoV synthetic vector via a 12-nt insertion (note the CGG codon for the leading arginine): Image
In 2016-17, WIV has created a novel reverse genetics system ("backbone") for the WIV1 virus, and Shibo Jiang subsequently coauthored a paper with Lei-Ping Zeng, the author of that backbone. (Lanying Du, another key collaborator of both WIV and Shibo Jiang, was also on the paper. She was also the editor for the 2013 paper inserting the RIRR FCS):

pmc.ncbi.nlm.nih.gov/articles/PMC70…
Read 20 tweets
Jul 13, 2024
🚀 More amazing partial reprogramming news! This time from @davidasinclair — he mentioned some unpublished animal results for:

- *reversing* Alzheimer’s symptoms
- hearing loss
- ALS
- glaucoma (anticipating clinical trials in 2025!)
- rejuvenating skin, kidneys and liver
Great to hear that the FDA is ok with Tet-inducible (via rtTA3) partial reprogramming gene therapies, and that Life Bio is so close to the clinic. They presented encouraging results in monkeys in an eye stroke model (NIAON); I didn’t know they also tried a glaucoma monkey model.


Image
Image
Image
Image
PS: while Life Bio seems closest to human clinical trials among partial reprogramming companies, others aren’t far behind:

- Turn Bio with their skin therapy
- we at YouthBio with our Alzheimer’s therapy
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(